Cocrystal Pharma

Cocrystal Pharma appointed Carol L. Brosgart as director with immediate effect, the company said in a press release filed with the SEC. The appointment comes as the biotech, with a market capitalization of $20.8 million and regarded as overvalued at a share price of $1.08 according to analysis, reported a loss of $0.76 per share over the past twelve months. The filing states there are no arrangements, family relationships or reportable transactions involving Brosgart. Cocrystal Pharma also announced the immediate appointment of James Sapirstein as the new chief executive officer; his compensation package includes a base salary of $265,000 and a performance-based bonus of up to 50%. » More on de.investing.com

Cocrystal Pharma has appointed Dr. Carol Brosgart to its board effective August 12. Brosgart brings decades of experience in antiviral therapy, epidemiology and regulatory processes, including from her time at Gilead Sciences and various board roles. The company is advancing the clinical development of antiviral therapeutics, including CDI-988 against noroviruses. » More on de.investing.com

Cocrystal Pharma appointed James Sapirstein effective June 3, 2026, as chief executive officer. His contract provides a base salary of $265,000 per year, a performance-based bonus of up to 50%, and, for the first time, options to purchase 235,000 common shares (exercise price $1.05) that vest over four years; an additional grant of up to 235,000 options may be made after six months. In the event of a change of control, all unvested options become immediately exercisable; if he is terminated without cause, 50% of the unvested options immediately vest. The biotech has a market capitalization of about $13.93 million, a loss of $0.72 per share over the past 12 months and high cash burn, but more cash than debt; concurrently, oral candidate CDI-988 received FDA Fast Track status and a phase‑1b human challenge study is underway. » More on de.investing.com